MedTrace Logo

Transcranial Magnetic Stimulation for Freezing of Gait in Parkinson's Disease

NCT07731841 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2026-07-28

No results posted yet for this study

Summary

This study evaluated transcranial magnetic stimulation (TMS) for freezing of gait in patients with Parkinson's disease. Participants with Parkinson's disease and freezing of gait received conventional TMS protocols, and their clinical, gait, and neurophysiological outcomes were assessed. Patients who did not achieve sufficient improvement after conventional TMS were further treated with a combined primary motor cortex and cerebellar stimulation protocol. The study aimed to identify factors associated with differential response to conventional TMS and to explore whether cerebellar stimulation could improve symptoms in treatment-resistant patients.

Conditions

  • Parkinson Disease (PD)

Interventions

DEVICE

Primary Motor Cortex Transcranial Magnetic Stimulation

Bilateral lower-limb primary motor cortex stimulation was delivered at 10 Hz and 90% of resting motor threshold, with 2000 pulses per hemisphere. Treatment was administered once daily for five consecutive days per week over two weeks.

DEVICE

Spinal Cord Magnetic Stimulation

Transcutaneous spinal magnetic stimulation was delivered over the T10-T12 segment at 1 Hz, with 1500 pulses. Stimulation intensity was adjusted to produce visible lower-limb muscle contraction.

DEVICE

SMA TMS

Supplementary motor area stimulation was delivered at 10 Hz and 90% of resting motor threshold, with 1000 pulses. Treatment was administered as an add-on protocol combined with bilateral lower-limb primary motor cortex stimulation.

DEVICE

Cerebellar Intermittent Theta-Burst Stimulation

Bilateral cerebellar intermittent theta-burst stimulation was delivered using 50-Hz triplets at 5 Hz, with 2-second trains every 10 seconds and a total of 2700 pulses over 15 minutes. This intervention was administered to patients who were treatment-resistant to conventional TMS.

Sponsors & Collaborators

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2025-12-30
Completion
2026-06-23

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07731841 on ClinicalTrials.gov